[
1. Yoshida H, Ishiko O, Sumi T, Matsumoto Y, Ogita S. Survivin, bcl-2 and matrix metalloproteinase-2 enhance progression of clear cell- and serous-type ovarian carcinomas. Int J Oncol. 2001;19(3):537–42.10.3892/ijo.19.3.537
]Search in Google Scholar
[
2. Cancer incidence in Bulgaria, 2014-2015. Bulgarian National Cancer Registry 2015. (full text: http://www.sbaloncology.bg/bg/bulgarian-cancer-registry.html)
]Search in Google Scholar
[
3. Chandra A, Pius C, Nabeel M, Nair M, Vishwanatha JK, Ahmad S et al. Ovarian cancer: Current status and strategies for improving therapeutic outcomes. Cancer medicine. 2019 Nov;8(16):7018-31.10.1002/cam4.2560
]Search in Google Scholar
[
4. Rastogi M, Gupta S, Sachan M. Biomarkers towards ovarian cancer diagnostics: present and future prospects. Brazilian archives of biology and technology. 2016 Oct 31;59.10.1590/1678-4324-2016160070
]Search in Google Scholar
[
5. Kim B, Park Y, Kim B, Ahn HJ, Lee KA, Chung JE et al. Diagnostic performance of CA 125, HE 4, and risk of Ovarian Malignancy Algorithm for ovarian cancer. Journal of clinical laboratory analysis. 2019 Jan;33(1):e22624.10.1002/jcla.22624
]Search in Google Scholar
[
6. Nolen BM, Lokshin AE. Protein biomarkers of ovarian cancer: the forest and the trees. Future Oncol. 2012 Jan;8(1):55-71.10.2217/fon.11.135
]Search in Google Scholar
[
7. Jacobs IJ, Menon U. Progress and challenges in screening for early detection of ovarian cancer. Mol Cell Proteomics. 2004;3(4):355-66.10.1074/mcp.R400006-MCP200
]Search in Google Scholar
[
8. Menon U, Jacobs IJ. Ovarian cancer screening in the general population: current status. Int J Gynecol Cancer. 2001;11(Suppl 1):3-610.1046/j.1525-1438.2001.11(suppl.1)sup1003.x
]Search in Google Scholar
[
9. Kim YW, Bae SM, Lim H, Kim YJ, Ahn WS. Development of multiplexed bead-based immunoassays for the detection of early stage ovarian cancer using a combination of serum biomarkers. PLoS One. 2012;7(9): e44960.10.1371/journal.pone.0044960343817522970327
]Search in Google Scholar
[
10. Zhang Z, Bast RC Jr, Yu Y, Li J, Sokoll LJ, Rai AJ et al. Three biomarkers identified from serum proteomic analysis for the detection of early stage ovarian cancer. Cancer Res. 2004 Aug 15;64(16):5882-90.10.1158/0008-5472.CAN-04-074615313933
]Search in Google Scholar
[
11. Clarke CH, Yip C, Badgwell D, Fung ET, Coombes KR, Zhang Z, Lu KH, Bast Jr RC. Proteomic biomarkers apolipoprotein A1, truncated transthyretin and connective tissue activating protein III enhance the sensitivity of CA125 for detecting early stage epithelial ovarian cancer. Gynecologic oncology. 2011 Sep 1;122(3):548-53.10.1016/j.ygyno.2011.06.002315264621708402
]Search in Google Scholar
[
12. Rosen DG, Wang L, Atkinson JN, Yu Y, Lu KH, Diamandis EP, Hellstrom I, Mok SC, Liu J, Bast Jr RC. Potential markers that complement expression of CA125 in epithelial ovarian cancer. Gynecologic oncology. 2005 Nov 1;99(2):267-77.10.1016/j.ygyno.2005.06.040
]Search in Google Scholar
[
13. Anderson GL, McIntosh M, Wu L, Barnett M, Goodman G, Thorpe JD, Bergan L, Thornquist MD, Scholler N, Kim N, O‘Briant K. Assessing lead time of selected ovarian cancer biomarkers: a nested case–control study. Journal of the National Cancer Institute. 2010 Jan 6;102(1):26-38.10.1093/jnci/djp438
]Search in Google Scholar
[
14. Palmer C, Duan X, Hawley S, Scholler N, Thorpe JD, Sahota RA, Wong MQ, Wray A, Bergan LA, Drescher CW, McIntosh MW. Systematic evaluation of candidate blood markers for detecting ovarian cancer. PLoS One. 2008 Jul 9;3(7):e2633.10.1371/journal.pone.0002633
]Search in Google Scholar
[
15. Mählck CG, Grankvist K. Plasma prealbumin in women with epithelial ovarian carcinoma. Gynecol Obstet Invest. 1994;37(2):135-40.10.1159/000292542
]Search in Google Scholar
[
16. Kuesel AC, Kroft T, Préfontaine M, Smith IC. Lipoprotein (a) and CA125 levels in the plasma of patients with benign and malignant ovarian disease. International journal of cancer. 1992 Sep 30;52(3):341-6.10.1002/ijc.2910520302
]Search in Google Scholar
[
17. Gadomska H, Grzechocińska B, Janecki J, Nowicka G, Powolny M, Marianowski L. Serum lipids concentration in women with benign and malignant ovarian tumours. European Journal of Obstetrics & Gynecology and Reproductive Biology. 2005 May 1;120(1):87-90.10.1016/j.ejogrb.2004.02.045
]Search in Google Scholar
[
18. Liu Y, Chen S, Zheng C, Ding M, Zhang L, Wang L et al. The prognostic value of the preoperative c-reactive protein/albumin ratio in ovarian cancer. BMC cancer. 2017 Dec;17(1):1-8.10.1186/s12885-017-3220-x
]Search in Google Scholar
[
19. Shan W, Liu J. Inflammation: a hidden path to breaking the spell of ovarian cancer. Cell Cycle. 2009 Oct 1;8(19):3107-11.10.4161/cc.8.19.9590
]Search in Google Scholar
[
20. 20. Balkwill F, Mantovani A. Inflammation and cancer: back to Virchow? The Lancet. 2001 Feb 17;357(9255):539-45.10.1016/S0140-6736(00)04046-0
]Search in Google Scholar
[
21. Espey LL. Current status of the hypothesis that mammalian ovulation is comparable to an inflammatory reaction. Biology of reproduction. 1994 Feb 1;50(2):233-8.10.1095/biolreprod50.2.2338142541
]Search in Google Scholar
[
22. Fathalla MF. Incessant ovulation—a factor in ovarian neoplasia. Lancet. 1971 Jul 17;2(7716):163.10.1016/S0140-6736(71)92335-X
]Search in Google Scholar
[
23. Ness RB, Grisso JA, Cottreau C, Klapper J, Vergona R, Wheeler JE et al. Factors related to inflammation of the ovarian epithelium and risk of ovarian cancer. Epidemiology. 2000 Mar 1;11(2):111-7.10.1097/00001648-200003000-00006
]Search in Google Scholar
[
24. Modugno F, Ness RB, Allen GO, Schildkraut JM, Davis FG, Goodman MT. Oral contraceptive use, reproductive history, and risk of epithelial ovarian cancer in women with and without endometriosis. American journal of obstetrics and gynecology. 2004 Sep 1;191(3):733-40.10.1016/j.ajog.2004.03.035
]Search in Google Scholar
[
25. Green A, Purdie D, Bain C, Siskind V, Russell P, Quinn M et al. Tubal sterilisation, hysterectomy and decreased risk of ovarian cancer. International Journal of Cancer. 1997 Jun 11;71(6):948-51.10.1002/(SICI)1097-0215(19970611)71:6<948::AID-IJC6>3.0.CO;2-Y
]Search in Google Scholar
[
26. Cramer DW, Bast RC, Berg CD, Diamandis EP, Godwin AK, Hartge P et al. Ovarian cancer biomarker performance in prostate, lung, colorectal, and ovarian cancer screening trial specimens. Cancer Prevention Research. 2011 Mar 1;4(3):365-7410.1158/1940-6207.CAPR-10-0195
]Search in Google Scholar
[
27. Klaunig JE, Kamendulis LM. The role of oxidative stress in carcinogenesis. Annu. Rev. Pharmacol. Toxicol. 2004 Feb 10;44:239-67.10.1146/annurev.pharmtox.44.101802.121851
]Search in Google Scholar
[
28. Janero DR. Malondialdehyde and thiobarbituric acid-reactivity as diagnostic indices of lipid peroxidation and peroxidative tissue injury. Free radical biology and medicine. 1990 Jan 1;9(6):515-40.10.1016/0891-5849(90)90131-2
]Search in Google Scholar
[
29. Jacobs I, Bast Jr RC. The CA 125 tumour-associated antigen: a review of the literature. Human reproduction. 1989 Jan 1;4(1):1-2.10.1093/oxfordjournals.humrep.a136832
]Search in Google Scholar
[
30. Bast RC Jr, Xu FJ, Yu YH, Barnhill S, Zhang Z, Mills GB. CA 125: the past and the future. Int J Biol Markers. 1998 Oct-Dec;13(4):179-87. PMID: 10228898.10.1177/172460089801300402
]Search in Google Scholar
[
31. Cohen LS, Escobar PF, Scharm C, Glimco B, Fishman DA. Three-dimensional power Doppler ultrasound improves the diagnostic accuracy for ovarian cancer prediction. Gynecologic oncology. 2001 Jul 1;82(1):40-8.10.1006/gyno.2001.6253
]Search in Google Scholar
